Impact BioMedical Says On July 21, 2025, Co Converted $12M Debt To Equity With DSS Through Issuance Of 31.9M Shares

On July 21, 2025, Impact BioMedical Inc. (the "Company" or "Borrower") entered into a Debt Conversion Agreement with DSS, Inc. ("DSS" or "Lender"), pursuant to that certain loan made on March 31, 2023, by the Lender in the form of a revolving promissory note in the original amount of $12,000,000 (the "Original Note"), which was amended on January 18, 2024 to (i) extend the maturity date of the Loan to September 30, 2023, (ii) eliminate any advance feature under the terms of the Original Note, (iii) establish specific repayment terms of the Loan balance, and (v) to amend the interest rate to a market rate of interest (WSJ Prime + 0.5%).

In connection with the above, the Company and DSS have agreed to settle the outstanding Debt owed to DSS, in which the Borrower shall issue to the Lender 31,939,778 shares of freely tradeable common stock of the Company, par value $0.001 per share (the "Shares") in full and final satisfaction of the Original Note and any amendments thereto and all amounts owed thereunder as of the closing of the transaction, and any and all additional financial or operations support, credit, or services extended by the Lender of its affiliates to Borrower between June 21, 2025 and the transaction closing date.

The foregoing summary of the terms of the Debt Conversion Agreement is qualified in its entirety by reference to the text of the Debt Conversion Agreement, which is filed hereto as Exhibit 10.1 and is incorporated herein by reference.